Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 6, 2004, Pages 583-893

  Djukanović, Ratko ^a   Wilson, Susan J ^b   Kraft, Monica ^b   Jarjour, Nizar N ^b   Steel, Mark ^b   Chung, K Fan ^b   Bao, Weibin ^b   Fowler Taylor, Angel ^b   Matthews, John ^b   Busse, William W ^b   Holgate, Stephen T ^b   Fahy, John V ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

Eosinophils; High affinity Fc receptor for IgE, Fc RI; Interleukin 4

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 4; METHACHOLINE; OMALIZUMAB;

ADULT; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BODY WEIGHT; BRONCHOSCOPY; BRONCHUS BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EOSINOPHILIA; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; SPUTUM ANALYSIS; SPUTUM CYTODIAGNOSIS; T LYMPHOCYTE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHI; DOUBLE-BLIND METHOD; EOSINOPHILIA; FEMALE; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; MALE; MIDDLE AGED; RESPIRATORY MUCOSA; SPUTUM; TREATMENT OUTCOME;

EID: 4444232912     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200312-1651OC     Document Type: Article

References (49)

1. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-277.
2. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325:1067-1071.
3. Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996;183:1303-1310.
4. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001;164:S1-S5.
5. Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol 1999;104:S132-S137.
6. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanović R, Mueller R, Heusser CH, Howarth PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-480.
7. Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997;99:155-160.
8. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-1705.
9. Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal asthmatic subjects. Eur Respir J 2002;19:879-885.
10. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-1840.
11. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-1834.
12. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-1973.
13. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261.
14. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
15. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G, vanAs A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
16. Shields R, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG, Thomas D, Saban R, Jardieu P. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995;107:308-312.
17. εRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Clin Immunol 1997;158:1438-1445.
18. Tumas DB, Chan B, Werther W, Wrin T, Vennari J, Desjardin N, Shields RL, Jardieu P. Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization. J Allergy Clin Immunol 2001;107:1025-1033.
19. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafsson H, Sandstrom T, Rak S. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:68-71.
20. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.
21. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-1721.
22. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491-498.
23. National Institutes of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Washington, DC: U.S. Government Printing Office; 1997. NIH Publication No. 97-4051.
24. Claman D, Boushey HA, Liu J, Wong H, Fahy JV. Analysis of induced sputum to examine the effects of prednisone on airway inflammation. J Allergy Clin Immunol 1994;94:861-869.
25. Djukanović R, Dahl R, Jarjour N, Aalbers R. Safety of biopsies and bronchoalveolar lavage. Eur Respir J Suppl 1998;26:39S-41S.
26. Djukanović R, Feather I, Gratziou C, Walls A, Peroni D, Brading P, Judd M, Howarth PH, Holgate ST. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax 1996;51:575-581.
27. Djukanović R, Homeyard S, Gratziou C, Madden J, Walls A, Montefort S, Peroni D, Polosa R, Holgate ST, Howarth P. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am J Respir Crit Care Med 1997;155:826-832.
28. Humbert M, Grant JA, Taborda-Barata L, Durham SR, Pfister R, Menz G, Barkans J, Ying S, Kay AB. High-affinity IgE receptor (FcεRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996;153:1931-1937.
29. Djukanović R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, Holgate ST. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-457.
30. Kay AB, Frew AJ, Moqbel R, Walsh GM, Kurihara K, Cromwell O, Champian A, Hartnell A, Wardlaw AJ. The activated eosinophil in allergy and asthma. Prog Clin Biol Res 1989;297:183-196.
31. Lim S, Jatakanon A, John M, Gilbey T, O'Connor BJ, Chung KF, Barnes PJ. Effect of inhaled budesonide on lung function and airway inflammation: assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999;159:22-30.
32. Djukanović R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-674.
33. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999;54:403-408.
34. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone MA Jr, McIntyre BW, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992;148:1086-1092.
35. Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, Howarth PH. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects: the mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993;151:3853-3865.
36. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, Hamid Q. Dysregulation of interleukin 4, interleukin 5, and Interferon γ gene expression in steroid-resistant asthma. J Exp Med 1995;181:33-40.
37. van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993;150:3643-3650.
38. Kehry MR, Yamashita LC. Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc Natl Acad Sci USA 1989;86:7556-7560.
39. εR2/CD23 on normal human monocytes. J Exp Med 1988;167:1406-1416.
40. εR2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and γ interferon. J Exp Med 1989;170:309-314.
41. Semper AE, Hartley JA, Tunon-de-Lara JM, Bradding P, Redington AE, Church MK, Holgate ST. Expression of the high affinity receptor for immunoglobulin E (IgE) by dendritic cells in normals and asthmatics. Adv Exp Med Biol 1995;378:135-138.
42. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
43. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma. Am J Respir Crit Care Med 2003;167:1655-1659.
44. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthma. J Clin Invest 2003;112:1029-1036.
45. O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503-508.
46. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM, IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-970.
47. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:1816-1823.
48. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131:46-52.
49. Rabe K. Mechanisms of immune sensitization of human bronchus. Am J Respir Crit Care Med 1999;158:S161-S170.